Dr. List is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
280 Jefferson Rd
Princeton, NJ 08540Phone+1 609-924-1381
Education & Training
Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2000 - 2003
Brigham and Women's Hospital/Children's Hospital/Harvard Medical SchoolResidency, Internal Medicine/Pediatrics, 1996 - 2000
University of Minnesota Medical SchoolClass of 1996
Certifications & Licensure
MA State Medical License 1998 - 2025
NJ State Medical License 2013 - 2025
TX State Medical License 2003 - 2008
Publications & Presentations
PubMed
- 124 citationsGlucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humansJames F. List, Jean M. Whaley
Kidney International. Supplement. 2011-03-01 - 485 citationsLong-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic...Donald E. Kohan, Paola Fioretto, Weihua Tang, James F. List
Kidney International. 2014-04-01 - 161 citationsExploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot StudyRobert R. Henry, Julio Rosenstock, Steven V. Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris
Diabetes Care. 2015-03-01
Journal Articles
- New Clinical Trial Designs for Establishing Drug Efficacy and Safety in a Precision Medicine EraJames List, MD, Diabetes, Obesity and Metabolism
Press Mentions
Late-Breaking Phase 3 a DUE Data Show Investigational Single-Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Haemodynamics Versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)March 6th, 2023- Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual MeetingOctober 1st, 2022
- Johnson & Johnson : The Janssen Pharmaceutical - New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO (Rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related EventsSeptember 30th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
